Codexis (CDXS) Misses Q3 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Codexis Reports Third Quarter 2023 Financial Results
November 2, 2023 4:05 PM EDTCompany Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis Platform for RNAi Therapeutics Production by End of Year
Strong Financial Position Enables Projected Runway to Expected Positive Cash Flow Around End of 2026
Company to Host Virtual ECO Synthesis Platform-Focused KOL Event on December 8, 2023, featuring John Maraganore
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the third quarter ended September 30, 2023,... More
